Idarucizumab

Idarucizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetDabigatran
Names
Trade namesPraxbind
Other namesBI-655075
Clinical data
Main usesReversal of dabigatran[1]
Side effectsHeadache, nausea, constipation[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: B2
    Routes of
    use    		Intravenous
    Typical dose5 gram[1]
    External links
    AHFS/Drugs.comMonograph
    Legal
    License data
    Legal status
    Chemical and physical data
    FormulaC2131H3299N555O671S11
    Molar mass47782.71 g·mol−1

    Idarucizumab, sold under the brand name Praxbind, is a medication used to reverse the effects of dabigatran.[1] Specifically it is used if severe bleeding or urgent surgery is required.[1] It is given by injection into a vein.[3]

    Common side effects include headache, nausea, and constipation.[1] Severe side effects may include blood clots and allergic reactions.[1] It is a monoclonal antibody that works by binding to and inactivating dabigatran.[1][2]

    Idarucizumab was approved for medical use in the United States and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £2,400 for a dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[4]

    Medical uses

    Dabigatran can be started again once 24 hours has passed from this medication being given.[3]

    Dosage

    It is given as a dose of 5 gram.[1] Occasionally a second 5 gram dose may be used.[3]

    Society and culture

    Names

    Idarucizumab is the International nonproprietary name (INN).[5] The description was updated in 2016.[6] Idarucizumab is the United States Adopted Name (USAN).[7]

    See also

    References

    1. 1 2 3 4 5 6 7 8 9 10 11 "Praxbind- idarucizumab injection". DailyMed. 1 December 2019. Archived from the original on 25 March 2021. Retrieved 19 August 2020.
    2. 1 2 3 "Praxbind EPAR". European Medicines Agency (EMA). Archived from the original on 25 October 2020. Retrieved 16 October 2020.
    3. 1 2 3 4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 131. ISBN 978-0857114105.
    4. ↑ "Praxbind Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 2 May 2021. Retrieved 25 November 2021.
    5. ↑ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
    6. ↑ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.
    7. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab Archived 2015-06-27 at the Wayback Machine, American Medical Association.
    External sites:
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.